A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib versus Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.MK-2870/022-PARPi (EvoPAR Ovarian01)

“Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy.GINECO/MK-2870-021

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer.DESTINY-OVARIAN 01

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.

“A Phase 2 study evaluating the efficacy and safety of TORL-1-23 in Women with advanced platinum-resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6 (CLdn6)” NOGGO/TORL

Randomized Phase 3 Trial for Mirvetuximab + Bevatuximab manteinance in FR@High PSOC Patients

A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase III, multi-center, randomized (1:1), open label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy (wPac or PLD), in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC

A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of patients with recurrent ovarian cancer not suitable for platinum treatment (ROC-NP)

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)”

“A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer”RAINFOL-OV2

A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer”

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer”

Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer

PHASE II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer.NADIA

A Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. A Phase II, multicenter, prospective, open-label, randomized, controlled study.

A phase III, Randomized, Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus treatment of Physician´s choice in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer who progress after Platinum-based Chemotherapy and Anti PD-1/anti-PD-L1 therapy

“A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer.”

An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer”(DESTINY)

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan versus Standard of Care (Carboplatin in Combination with Paclitaxel) as Adjuvant Treatment for HER2-expressing (IHC 3+/IHC 2+) Endometrial Cancer

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

“A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer

A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma

Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting)

“A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy”

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

A Phase 3Trial with Durvalumab-Olaparib in Newly Diagnosed Advanced and Recurrent endometrial cancer

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

A phase 3, randomized, double blind multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advance endometrial cancer

An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL

An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL

Caroline meets HANNA – Holistic Analysis of LoNgterm-survival with OvariaNCAncer.

Phase II studyofOlaparib as maintenanceTherapyafter response totrabectedin-pegylatedliposomaldoxorubicin in recurrentovarian carcinoma.

Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.

Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.

Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.

A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.

Ensayo clínico fase II de quimioterapia neoadyuvante con o sin Bevacizumab en pacientes con cáncer de ovario.

F III, mantenimiento con niraparib vs placebo en recaída platino sensible.

F III Olaparib vs placebo de mantenimiento tras recaída platino-sensible.

F III cirugía o no en la recaída platino sensible.

F III QT +/- pertuzumab en platino-resistente.

Estudio retrospectivo sobre tratamiento del cáncer de ovario.

Estudio post-autorización observacional restrospectivo y multicéntrico de la combinación con trabectedina y doxorubicinaliposomalpegilada (DLP) en cáncer de ovario recidivante.

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

TRINOVA – A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.

Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers.

Estudio de Fase II-III de quimioterapia intraperitoneal (IP) más intravenosa (IV) frente a carboplatino más Paclitaxel IV en pacientes con carcinoma epitelial de ovario sometidas a cirugía citoreductora óptima posterior a quimioterapia intravenosa neoadyuvante.

Ensayo Fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación de pacientes con un carcinoma epitelial de ovario, de trompa de Falopio, o un carcinoma primario peritoneal en segunda o tercera remisión completa clínica.

Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con carboplatino y paclitaxel en pacientes con cáncer de ovario avanzado.

Ensayo clínico fase II no controlado, multicéntrico y prospectivo para determinar el beneficio clínico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR -1, -2 , -3, PDGFR-α y β y C-Kit), en pacientes con cáncer de ovario avanzado platino resistentes.

Ensayo clínico multicéntrico del Gynaecologic Cancer Intergroup, controlado doble ciego de Cediranib (AZD 2171), en combinación con quimioterapia basada en platino y como agente único en terapia de mantenimiento, en mujeres con cáncer de ovario que han recaído más de 6 meses tras la finalización de un tratamiento de primera línea basado en platino.

AURELIA: Ensayo clínico de fase III multicéntrico, abierto, aleatorizado, con dos grupos de tratamiento, de bevacizumab en combinación con quimioterapia frente a quimioterapia sola en pacientes con cáncer epitelial de ovario, carcinoma de trompas de Falopio o peritoneal primario resistente a platino.

Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mujeres con cáncer epitelial de ovario, de trompa de Falopio o peritoneal primario que no hayan progresado después de la quimioterapia de primera línea.

A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.

Topotecán más carboplatino frente al tratamiento estándar (paclitaxel más carboplatino o gemcitabina más carboplatino) en el tratamiento de pacientes con carcinoma peritoneal, carcinoma de trompas o carcinoma epitelial de ovario plantino-sensibles recidivantes.

Base de datos de Bevacizumab en recaídas de Cáncer de Ovario.

Estudio retrospectivo de biomarcadores en Cáncer Epitelial de Ovario.

Feasibility and toxicity of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.

Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer epitelial de ovario.

Determinación de la expresión de TOPO IIA en muestras de carcinoma de ovario de pacientes tratadas con doxorubicina liposomal pegilada.

Ensayo clínico multicéntrico aleatorizado, doble ciego, controlado con placebo, para evaluar el tratamiento de mantenimiento con abagovomab en pacientes afectas de carcinoma epitelial ovárico tras respuesta completa a la quimioterapia de la 1ª línea.

Estudio fase II randomizado del doblete carboplatino-gemcitabina seguido de carboplatino paclitaxel versus carboplatino-paclitaxel en pacientes con recidiva platinosensible de carcinoma de ovario, carcinomatosis peritoneal primaria o carcinoma de trompa.

Ensayo clínico de fase III para evaluar el tratamiento con la combinación cisplatino más topotecán seguido de paclitaxel más carboplatino frente a paclitaxel más carboplatino como tratamiento de primera línea en mujeres con un diagnóstico reciente de cáncer epitelial de ovario avanzado.

Estudio fase II, con Gemcitabina en infusión prolongada en pacientes con cáncer epitelial de ovario avanzado resistentes a platino

Validación por GEICO de CAELYX en pacientes con cáncer epitelial de ovario.

Ensayo clínico fase II randomizado (con valoración de calidad de vida) de carboplatino frente a la combinación de taxol y carboplatino en pacientes con recaída de cáncer de ovario platino-sensible.

Ensayo Clínico aleatorizado de Paclitaxel / Epirubicina / Carboplatino en combinación (TEC) vs Paclitaxel / Carboplatino (TC) en el tratamiento de mujeres con cáncer de ovario avanzado.

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Multicentric Single arm Phase II clinical trial, to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients

Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer

Randomized Phase III MEK152 vs chemo Low Grade Serous Ovarian Cancer

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance

A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.

Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

A Phase 2 Trial of TisotumabVedotin (HuMax®-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.

Estudio de fase II, de tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante.

Phase 3 of ADX11-001 administered following chemoradiation as adjuvant treatment for HRLACC.

Fase II carbo-paclitaxel-bevacizumab en primera línea del carcinoma de cérvix persistente, recurrente o diseminado.

Ensayo en Fase III aleatorizado de Cisplatino más Paclitaxel con y sin Bevacizumab frente al doblete sin platino, Topotecan más Paclitaxel, con y sin Bevacizumab, en carcinoma de cérvix en estadio IVB, recurrente o persistente.

Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con derivados del platino.

Randomized, open-label, phase III clinical trial of REGN2810 compared to investigator's choice chemotherapy treatment for recurrent or metastatic platinum-resistant cervical carcinoma

Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.

Yondelis en leiomiosarcoma uterino: estudio retrospectivo + biomarcadores.

Ensayo Fase IV-II de Temozolamida en esquema de administración oral continua en el tratamiento de los Sarcomas Ginecológicos.

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA

A PHASE II MULTICENTER, OPEN-LABEL, SINGLE ARM TRIAL OF AVELUMAB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT/METASTATIC ENDOMETRIAL CANCER

Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma

A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Platinum-sensitive Ovarian Cancer

Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, High-grade Serous Ovarian Cancer

A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option

A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.

A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)